NewAmsterdam Pharma (NAMS) Assets Average (2022 - 2026)

NewAmsterdam Pharma (NAMS) has 4 years of Assets Average data on file, last reported at $751.0 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 10.76% year-over-year to $751.0 million; the trailing twelve-month figure through Mar 2026 stood at $751.0 million (down 10.76% YoY), and the FY2025 full-year result was $817.0 million, up 34.84% from the prior year.
• Assets Average retreated to $751.0 million in Q1 2026, from $777.9 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $841.5 million in Q1 2025 to a low of $305.4 million in Q4 2022.
• A 4-year average of $627.3 million and a median of $701.4 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average jumped 101.43% in 2025 and slipped 10.76% in 2026, its largest moves.
• Tracing NAMS's Assets Average over 4 years: stood at $305.4 million in 2022, then jumped by 113.48% to $651.9 million in 2024, then grew by 19.32% to $777.9 million in 2025, then decreased by 3.46% to $751.0 million in 2026.
• Business Quant data shows NAMS's Assets Average at $751.0 million in Q1 2026, $777.9 million in Q4 2025, and $800.8 million in Q3 2025.